IP Library › Granted Patent US 11,852,632
Granted Patent B2
US 11,852,632 · App. 17/964,758 · Granted Dec 26, 2023

Cancer test device, cancer test method, and staining agent for use in cancer test

Inventors: Akira Mizoguchi (Mie, JP); Koji Tanaka (Mie, JP); Naoyuki Katayama (Mie, JP); Tetsuya Nosaka (Mie, JP); Kyosuke Tanaka (Mie, JP); Shujie Wang (Mie, JP); Aika Kaito (Mie, JP); Kousyoku Sai (Mie, JP); Kazushi Kimura (Mie, JP)
Assignee: Mie University
G01N33/57496A61B1/00G01N1/30G01N1/31G01N21/64G01N21/78G01N33/48C12M41/06G01N33/4833G01N33/50G01N33/574G01N2001/302
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,852,632
App. No.
17/964,758
Granted
Dec 26, 2023
Kind
B2
Abstract

A cancer test device ( 1 ) is provided with: an application unit ( 40 ) for applying a staining agent ( 45 ), which can selectively stain a product of a cancer-relating gene in a living cell a chromatic color, onto a group of living cells; an imaging unit ( 10 ) for imaging the group of living cells having the staining agent ( 45 ) applied thereto; and a determination unit ( 52 ) for determining the level of malignancy of cancerization of the group of living cells on the basis of the state of the stained expression pattern of the cancer-relating gene in the group of living cells in an image obtained by the aforementioned imaging.

Claims (12)

1. A cancer test method comprising:

an application step of applying a stain that selectively stains a cancer-related gene product of living cells in a chromatic color to a living cell group, wherein, the cancer-related gene product is STAT3-family cancer-related gene product that transmits a signal that promotes growth of the living cells and the stain is a curcumin-based compound;

an imaging step of imaging the living cell group to which the stain has been applied; and

an evaluation step of evaluating a grade of cancerization of the living cell group based on a staining state of the living cell group in an image produced by the imaging.

2. The cancer test method according to claim 1 ,

wherein an application unit applies the stain containing a curcumin-based compound to the living cell group and then applies the stain that stains a ras-family cancer-related gene product that transmits a signal that promotes growth of the living cells, wherein the stain is phloxine, erythrosine, merbromin, fast green FCF, or meclocycline sulfosalicylate to the living cell group.

3. The cancer test method according to claim 1 ,

wherein in the evaluation step, the evaluation is performed based on an area of a stained region of the living cell group.

4. The cancer test method according to claim 1 ,

wherein in the evaluation step, the evaluation is performed based on number of stained cells in a stained region of the living cell group.

5. The cancer test method according to claim 1 ,

wherein in the evaluation step, the evaluation is performed based on number and average diameter of stained cell groups in a fixed area containing a stained region of the living cell group.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2026
From: MIE UNIVERSITY
To: LASER BENEFIT LLC
Reel/Frame 075918/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2023
From: MIZOGUCHI, AKIRA; TANAKA, KOJI; KATAYAMA, NAOYUKI; NOSAKA, TETSUYA; TANAKA, KYOSUKE; WANG, SHUJIE; KAITO, AIKA; SAI, KOUSYOKU; KIMURA, KAZUSHI
To: MIE UNIVERSITY
Reel/Frame 065529/0873 →
Priority Claims (1)
JP 2016-099997 · May 18, 2016 · national
Continuity (3)
Division 16301939
Continuation PCTJP2017006962 · Feb 23, 2017
Related Publication 20230037210A1 · Feb 2, 2023